Novo Nordisk signs insulin deal with Caisson

11-03-2014

Novo Nordisk signs insulin deal with Caisson

Photo: Sherry Yates Young / Shutterstock.com

Texas-based biopharmaceutical company Caisson Biotech has expanded its partnership with diabetes therapy maker Novo Nordisk by giving Novo exclusive rights to commercialise an insulin treatment that uses Caisson’s drug delivery technology.


Novo Nordisk, Caisson, HEPtune, insulin, M&A

LSIPR